Axiogenesis Overview

  • Founded
  • 2000
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 32
Employees
  • Latest Deal Type
  • M&A

Axiogenesis General Information

Description

Producer of stem cell-based assays that enable drug development. The company's stem cell-based assays engage in production and use of transgenic and physiologically relevant tissues and cells derived from induced pluripotent stem cells and embryonic stem cells in drug development, enabling drug development enterprises to accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • Nattermannallee 1, Building S20
  • 50829 Cologne
  • Germany
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Axiogenesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 18-Sep-2017 Completed Generating Revenue
5. Later Stage VC 03-May-2016 Completed Generating Revenue
4. Later Stage VC 05-Jun-2012 Completed Generating Revenue
3. PIPE 23-Mar-2011 Completed Generating Revenue
2. IPO 19-Dec-2007 Completed Generating Revenue
1. Later Stage VC Completed Generating Revenue
To view Axiogenesis’s complete valuation and funding history, request access »

Axiogenesis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Producer of stem cell-based assays that enable drug development. The company's stem cell-based assays engage in producti
Biotechnology
Cologne, Germany
32 As of 2016
000000&0

00000000

m dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000 000000000
Cambridge, United Kingdom
00 As of 0000
00.000
0000000000 00.000

00000000

ute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Exc
0000000000000
Beit-Haemek, Israel
000 As of 0000
0000
000 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Axiogenesis Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
DefiniGEN Venture Capital-Backed Cambridge, United Kingdom 00 00.000 0000000000 00.000
0000000000 0000000 Formerly PE-Backed Beit-Haemek, Israel 000 0000 000000&0 0000
000 0000000000000 Venture Capital-Backed Seattle, WA 00 000.00 0000000000 0 000.00
00000000 00000000 Formerly VC-backed Madison, WI 000 00000 000000&0 00000
000000000 Formerly VC-backed Yokohama, Japan 000 000.00 00000000 000.00
You’re viewing 5 of 13 competitors. Get the full list »

Axiogenesis Executive Team (4)

Name Title Board Seat Contact Info
Michelle Stevens Director, Business Development
Brian Murphy Director, Marketing & Sales
Heribert Bohlen Ph.D Co-Founder & Chief Executive Officer
To view Axiogenesis’s complete executive team members history, request access »

Axiogenesis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axiogenesis Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Donghai Securities Holding Company Minority 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
Venture Plus Venture Capital Minority 000 0000 000000 0
To view Axiogenesis’s complete investors history, request access »